Full Press Release Details
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares.
ALXO
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Key Takeaway: ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)